Minimizing biological risk for novel inhibitory drug targets: One knockout is all you need
Dimitriev, A.; Postovit, L.-M.; Simpson, A. L.; Wong, G. K.-S.
Show abstract
We argue that biological risk for novel inhibitory drug targets can be minimized, almost eliminated, by a computational analysis of the healthcare records and DNA sequences in resources like UK Biobank or All-of-Us. The key insight is that an inhibitory drug is functionally equivalent to a loss-of-function (LOF) variant in the targeted gene. It is a special case of what has been called an "experiment of nature". To demonstrate, we considered all available clinical trials (58 in total) and inhibitory drugs (15 in total) for 5 cardiovascular drug targets: PCSK9, APOC3, ANGPTL3, LPA, and ASGR1. The results were shocking. Every biomarker assessed in these clinical trials was successfully predicted, i.e. directionality and proportionality of effect, but not the magnitude since that varies with dosage. This concept has not been widely adopted because geneticists believe that homozygous LOFs, which are exceedingly rare, would be needed to observe a significant phenotypic effect from most genetic knockouts. Our study shows that, to the contrary, given a sufficiently large biobank, counting both carriers and non-carriers, heterozygous LOFs alone can inform drug development.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Historical Cholesterol Exposure 95%
- Population genomic screening leads to improved lipid management in patients with familial hypercholesterolemia 94%
- Metabolic dysregulation of the lysophospholipid/autotaxin axis in the chromosome 9p21 gene SNP rs10757274 94%
Similar papers in this journal
- Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association study 94%
- Leveraging a genetic proxy to investigate the effects of lifelong cardiac sodium channel blockade 94%
- Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization Study 94%
Similar papers in this journal
- Identification of actionable genetic variants in 4,198 Scottish volunteers from the Viking Genes research cohort and implementation of return of results 94%
- Widespread recessive effects on common diseases in a cohort of 44,000 British Pakistanis and Bangladeshis with high autozygosity 93%
- Genetic association studies using disease liabilities from deep neural networks 93%
Similar papers in this journal
- Novel protein-altering variants associated with serum apolipoprotein and lipid levels 96%
- A loss-of-function CCR2 variant is associated with lower cardiovascular risk 94%
- Investigation of an LPA KIV-2 nonsense mutation in 11,000 individuals: the importance of linkage disequilibrium structure in LPA genetics. 94%
Similar papers in this journal
- The genetic underpinnings of variable penetrance and expressivity of pathogenic mutations in cardiometabolic traits 94%
- Clinical Impact of Pharmacogenetic Risk Variants in a Large Chinese Cohort 93%
- Biomarker panels for improved risk prediction and enhanced biological insights in patients with atrial fibrillation 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.